Hook
On-chain data tells a story that no press release can spin. Since January 2024, the wallet cluster associated with Baichuan’s core engineering team has transferred over 2,300 ETH to an exchange address – a pattern typically seen when key employees exit. At the same time, the project’s GitHub repository shows zero commits to its general-purpose model training pipeline in the last 90 days. The narrative of a “full-stack AI powerhouse” is collapsing, and the on-chain footprint is screaming the cause: a desperate pivot to medical verticalization after losing the race for general-purpose dominance.
Context
Baichuan Intelligence, launched in 2023 with a $700 million seed round ($50 billion RMB market cap), was marketed as a contender in the Chinese AI foundation model race. Its Baichuan-7B and 13B series briefly ranked in the top 10 domestic open-source models. But by late 2024, the competitive landscape shifted: models like Qwen, DeepSeek, and Yi had outpaced Baichuan in code generation and mathematical reasoning benchmarks. Co-founders Ru Liyun and others departed, citing strategic disagreements over AI coding agent development. The response? Wang Xiaochuan, the sole remaining founder, announced a full retreat from general-purpose (GP) model training and enterprise API services, redirecting all resources toward medical AI – specifically the M4 medical model and a family doctor agent named "Bai Xiaoyi."
Core: Systematic Teardown
The pivot is not a strategic masterstroke but a deterministic failure analysis made in public. Let’s break it down by code, capital, and control.
1. Smart Contract of the Model Stack Baichuan’s general-purpose model was a monolithic architecture requiring pre-training on 10,000+ H100 GPUs – a fixed cost of approximately $30 million per training run. The medical pivot replaces this with a fine-tuning pipeline on a fraction of the hardware. But here’s the catch: fine-tuning a base model (whether open-source like Llama or legacy Baichuan) does not create any moat. Any competitor can replicate the same strategy. The only real asset is proprietary medical data, and Baichuan has not disclosed a single data partnership with a Class III hospital. The GitHub reveals no HIPAA-compliant data pipeline, no no-code agent framework for clinicians. The codebase for "Bai Xiaoyi" is a single Jupyter notebook with hardcoded Q&A pairs. This is not production-grade. It’s a demo.
2. Tokenomics of Capital The $700 million raise was priced at a $2.8 billion valuation during the 2023 AI hype cycle. In the current market, with no API revenue (the enterprise business was shut down) and no medical revenue yet, that valuation is detached from reality. The burn rate is difficult to estimate, but typical GP model companies burn $2-4 million per month on compute alone. With the pivot, compute costs drop to ~$0.5 million per month, but medical compliance (NMPA certification, data governance) adds a new fixed cost of $5-10 million per product line. At this rate, Baichuan has 18-24 months of runway. The cohort of investors (Alibaba, Tencent, Sunshine Insurance) are now underwater on paper. No secondary token or equity sale has been recorded in the last six months, suggesting a down round is imminent.
3. Governance and Validator Set The departing co-founders were the equivalent of validators in a proof-of-stake network. Their exit slashes the project’s social consensus. Wang Xiaochuan now holds 100% voting power in the core team. This centralization is a red flag for institutional investors. The medical AI pivot further concentrates risk on a single regulatory bottleneck: obtaining a NMPA Class III medical device certificate. In crypto terms, it’s like relying on a single oracle for a $1 billion TVL protocol. One failure = total loss.
Contrarian: What the Bulls Got Right It would be dishonest to ignore the case for the bulls. Medical AI in China has genuine tailwinds: the government is pushing AI-assisted diagnosis into rural clinics, and the market for digital health is projected to reach $15 billion by 2027. Wang Xiaochuan’s prior experience with Sogou’s health Q&A gives him a thin but real distribution channel. If Baichuan’s M4 model can achieve a 95% accuracy in chest X-ray triage (a benchmark already hit by incumbents like Yitu), it could capture 5-10% of the hospital IT market within three years. The $700 million war chest, while burning, is still larger than any other medical AI startup in China. It can fund a marketing blitz that pushes "Bai Xiaoyi" into millions of WeChat mini-programs. The contrarian view is that Baichuan’s failure in GP models was priced in, and the pivot is a rational hedge. The market may be undervaluing the optionality of a cash-rich, founder-driven pivot in a high-regulation vertical.
But this argument relies on execution speed and regulatory luck – two variables that on-chain history rarely rewards.
Takeaway: Accountability Call
The data shows a project that has burned its initial advantage through indecision and now pins its survival on a single regulatory bet. The smart contract of its business model has been rewritten without an audit. Investors in the $700 million round should demand a transparency report: show the current cash balance, the number of active doctors using Bai Xiaoyi, and the NMPA application timeline. Code speaks louder than promises. Follow the gas, not the narrative. If in six months the GitHub shows no new medical data partnerships and the wallet cluster of the medical team remains empty, the proper judgment is not “pivot failed” but “the original thesis was always hollow.” Logic outlives the hype cycle.
Trust is verified, not given.